Cel-Sci (NYSEAMERICAN:CVM) Stock Price Up 6.9% – Time to Buy?

Cel-Sci Corporation (NYSEAMERICAN:CVM)’s stock price shot up 6.9% on Wednesday . The company traded as high as $3.60 and last traded at $3.43. 52,583 shares traded hands during trading, an increase of 56% from the average session volume of 33,663 shares. The stock had previously closed at $3.21.

Cel-Sci Stock Up 6.9%

The company has a debt-to-equity ratio of 0.45, a current ratio of 1.39 and a quick ratio of 1.35. The company has a market cap of $29.02 million, a P/E ratio of -0.35 and a beta of 0.99. The stock has a 50-day moving average of $4.44 and a 200 day moving average of $6.24.

Cel-Sci (NYSEAMERICAN:CVM) last posted its quarterly earnings results on Tuesday, December 23rd. The company reported ($0.76) EPS for the quarter. Research analysts anticipate that Cel-Sci Corporation will post -0.29 earnings per share for the current year.

Hedge Funds Weigh In On Cel-Sci

Hedge funds and other institutional investors have recently made changes to their positions in the company. US Bancorp DE acquired a new stake in shares of Cel-Sci during the 3rd quarter worth approximately $80,000. HighTower Advisors LLC bought a new position in Cel-Sci in the fourth quarter valued at approximately $53,000. XTX Topco Ltd acquired a new position in Cel-Sci during the fourth quarter valued at approximately $66,000. Renaissance Technologies LLC acquired a new position in Cel-Sci during the fourth quarter valued at approximately $81,000. Finally, Vanguard Group Inc. lifted its stake in Cel-Sci by 59.7% during the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after purchasing an additional 109,352 shares during the last quarter. 12.08% of the stock is currently owned by institutional investors and hedge funds.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.